NICE Technology Appraisal 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information.
Non-vitamin K oral anticoagulant options for patients with non-valvular atrial fibrillation and renal impairment
This NOAC dosing guide has been commissioned by Bayer, who also provided funding for its development. Bayer reviewed and approved the scope and pre-meeting documents, suggested the Chair and experts for the group, and put the dosing guide through full medical approval to ensure its compliance with appropriate regulations.